Signaturefd LLC Buys 821 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Signaturefd LLC increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 13.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,959 shares of the biotechnology company’s stock after purchasing an additional 821 shares during the quarter. Signaturefd LLC’s holdings in Exelixis were worth $232,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. USA Financial Formulas acquired a new position in shares of Exelixis in the 4th quarter valued at approximately $32,000. Principal Securities Inc. raised its position in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares in the last quarter. Kestra Investment Management LLC bought a new stake in Exelixis during the fourth quarter worth $39,000. Brooklyn Investment Group acquired a new stake in shares of Exelixis in the 3rd quarter valued at $42,000. Finally, UMB Bank n.a. increased its stake in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 553 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the transaction, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last quarter. 2.85% of the stock is currently owned by company insiders.

Exelixis Stock Down 0.6 %

Shares of NASDAQ EXEL opened at $36.96 on Friday. The company has a market capitalization of $10.34 billion, a PE ratio of 20.88, a P/E/G ratio of 1.13 and a beta of 0.57. The firm has a fifty day simple moving average of $35.61 and a 200 day simple moving average of $32.82. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXEL. Royal Bank of Canada raised their price objective on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Barclays raised their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler upped their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Stifel Nicolaus raised their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. Finally, Bank of America downgraded shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price target for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.